Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: Final results of the POBASCAM randomised controlled trial

The Lancet Oncology

Volumn 13, Issue 1, 2012, Pages 78-88

  Rijkaart, Dorien C ^a   Berkhof, Johannes ^a   Rozendaal, Lawrence ^a   van Kemenade, Folkert J ^a   Bulkmans, Nicole WJ ^a   Heideman, Daniëlle AM ^a   Kenter, Gemma G ^b   Cuzick, Jack ^c   Snijders, Peter JF ^a   Meijer, Chris JLM ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Centre for Gynaecological Oncology   (Netherlands)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA;

ADULT; AGE DISTRIBUTION; ARTICLE; CANCER GRADING; CANCER SCREENING; COMPUTER ASSISTED DIAGNOSIS; CONTROLLED STUDY; DIAGNOSTIC VALUE; DNA DETERMINATION; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS DNA TESTING; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN TISSUE; INTERVENTION STUDY; MAJOR CLINICAL STUDY; NONHUMAN; PAPILLOMAVIRUS INFECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY;

ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; DNA, VIRAL; EARLY DETECTION OF CANCER; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; MASS SCREENING; MIDDLE AGED; NEOPLASM GRADING; NETHERLANDS; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; TIME FACTORS; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 84855301170     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(11)70296-0     Document Type: Article

References (32)

1. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189:12-19.
2. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003, 348:518-527.
3. Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J Chapter 9: clinical applications of HPV testing: a summary of meta-analyses. Vaccine 2006, 24(suppl 3):S78-S89.
4. Cuzick J, Clavel C, Petry KU, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006, 119:1095-1101.
5. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006, 367:1247-1255.
6. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007, 356:1915-1927.
7. Bulkmans NWJ, Berkhof J, Rozendaal L, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007, 370:1764-1772.
8. Naucler P, Ryd W, Tornberg S, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007, 357:1589-1597.
9. Kitchener HC, Almonte M, Thomson C, et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol 2009, 10:672-682.
10. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 2010, 11:249-257.
11. Anttila A, Kotaniemi-Talonen L, Leinonen M, et al. Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: randomised study within organised screening programme. BMJ 2010, 340:c1804.
12. Bulkmans NW, Rozendaal L, Snijders PJ, et al. POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int J Cancer 2004, 110:94-101.
13. Bulk S, van Kemenade FJ, Rozendaal L, Meijer CJ The Dutch CISOE-A framework for cytology reporting increases efficacy of screening upon standardisation since 1996. J Clin Pathol 2004, 57:388-393.
14. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda system: terminology for reporting results of cervical cytology. JAMA 2002, 287:2114-2119.
15. Jacobs MV, Snijders PJ, van den Brule AJ, Helmerhorst TJ, Meijer CJ, Walboomers JM A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol 1997, 35:791-795.
16. van den Brule AJ, Pol R, Fransen-Daalmeijer N, Schouls LM, Meijer CJ, Snijders PJ GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J Clin Microbiol 2002, 40:779-787.
17. van Ballegooijen M, Hermens R Cervical cancer screening in the Netherlands. Eur J Cancer 2000, 36:2244-2246.
18. Hopman EH, Rozendaal L, Voorhorst FJ, Walboomers JM, Kenemans P, Helmerhorst TJ High risk human papillomavirus in women with normal cervical cytology prior to the development of abnormal cytology and colposcopy. BJOG 2000, 107:600-604.
19. Anderson MC Premalignant and malignant squamous lesions of the cervix. Obstetrical and gynaecological pathology 1995, 292-297. Chruchill Livingstone, New York. 4th edn. H. Fox, M. Wells (Eds.).
20. Wright TC Precancerous lesions of the cervix. Blaustein's pathology of the female genital tract 1995, 248-257. Springer Verslag, New York. 4th edn. R.J. Kurman (Ed.).
21. Rozendaal L, Walboomers JM, van der Linden JC, et al. PCR-based high-risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorphologically normal cervical smears. Int J Cancer 1996, 68:766-769.
22. Sankaranarayanan R, Nene BM, Shastri SS, et al. HPV screening for cervical cancer in rural India. N Engl J Med 2009, 360:1385-1394.
23. Dillner J, Rebolj M, Birembaut P, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 2008, 337:a1754.
24. Leinonen M, Nieminen P, Kotaniemi-Talonen L, et al. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting. J Natl Cancer Inst 2009, 101:1612-1623.
25. Meijer CJ, Berkhof J, Castle PE, et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer 2009, 124:516-520.
26. Van Den Brule AJ, Walboomers JM, Du Maine M, Kenemans P, Meijer CJ Difference in prevalence of human papillomavirus genotypes in cytomorphologically normal cervical smears is associated with a history of cervical intraepithelial neoplasia. Int J Cancer 1991, 48:404-408.
27. Meijer CJ, van den Brule AJ, Snijders PJ, Helmerhorst T, Kenemans P, Walboomers JM Detection of human papillomavirus in cervical scrapes by the polymerase chain reaction in relation to cytology: possible implications for cervical cancer screening. IARC Sci Publ 1992, 119:271-281.
28. Eluf-Neto J, Booth M, Muñoz N, Bosch FX, Meijer CJ, Walboomers JM Human papillomavirus and invasive cervical cancer in Brazil. Br J Cancer 1994, 69:114-119.
29. Walboomers JM, de Roda Husman AM, Snijders PJ, et al. Human papillomavirus in false negative archival cervical smears: implications for screening for cervical cancer. J Clin Pathol 1995, 48:728-732.
30. Remmink AJ, Walboomers JM, Helmerhorst TJ, et al. The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months. Int J Cancer 1995, 61:306-311.
31. Nobbenhuis MAE, Walboomers JMM, Helmerhorst TJM, et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet 1999, 354:20-25.
32. Gök M, Heideman DA, van Kemenade FJ, et al. HPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening: cohort study. BMJ 2010, 340:c1040.